1968-72-5

Upstream product

• 61948-84-3 2,3,4-trimethoxy-6-nitrobenzoic acid 
• 1967-88-0 6-amino-2,3,4-trimethoxybenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 24313-88-0 3,4,5-Trimethoxyaniline 
• 784-06-5 4,5,6-Trimethoxyisatin 
• 102439-00-9 3,4,5-trimethoxyaniline hydrochloride 
• 573-11-5 2,3,4-Trimethoxy-benzoic acid 
• 6395-18-2 methyl 2,3,4-trimethoxybenzoate 
• 1752-00-7 methyl 2,3,4-trimethoxy-6-nitrobenzoate 

Downstream Products

• 1752-02-9 methyl 6-iodo-2,3,4-trimethoxybenzoate 
• 80141-07-7 methyl 6-bromo-2,3,4-trimethoxybenzoate 
• 114605-78-6 1-bromo-4-isopropoxy-2,3-dimethoxybenzene 
• 50276-60-3 3,4,5-trimethoxyphthalic acid 
• 1173284-26-8 N-(4-fluorophenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-41-7 N-(3-chlorophenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-20-2 5,6,7-trimethoxy-N-(3-nitrophenyl)quinazoline-4-amine 
• 1173284-42-8 N-(2-fluorophenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-30-4 N-(2-chloro-4-bromophenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-35-9 N-(2-bromo-5-fluorophenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-40-6 N-(3-fluorophenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-29-1 N-(4-bromophenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-32-6 N-((2-fluoro-5-trifluoromethyl)phenyl)-5,6,7-trimethoxyquinazoline-4-amine 
• 1173284-33-7 5,6,7-trimethoxy-N-(4-(trifluoromethyl)phenyl)quinazoline-4-amine 

Relevant academic research and scientific papers

Synthesis and anticancer activities of 4-(4-substituted piperazin)-5,6,7-trialkoxy quinazoline derivatives

A series of 4-(4-substituted piperazin)-5,6,7-trialkoxy quinazoline was prepared by conventional heating methods. Among these compounds, the crystal structure of compound 10o (CCDC: 916922) was determined by X-ray crystallography. Bioassay results showed that most target compounds had certain inhibition activities against proliferation of tumor cells, and some compounds even had good broad-spectrum inhibition activities. The ethoxyl series of compounds possessed higher inhibition activities against tumor cells than the methoxyl series of compounds. Bioactivity tests showed that the IC50 values of compound 10s against PC3, MGC803, A375, and A549 cells were 1.8, 2.8, 1.3, and 2.9 μΜ, respectively, which were much higher than those of commercial gefitinib (7.2, 7.6, 7.2, and 9.8 μM, respectively). Conversely, the IC50 values of compound 10s were very low against NH3T3, indicating only weak effect on normal cells as also proven by lactate dehydrogenase and acridine orange/ethidium bromide staining. Analyses of cell configuration and cell cycle revealed that compound 10s possibly caused cells to remain at G0/G1 phase by inhibiting cell proliferation for 24 h. Compound 10s also inhibited the phosphorylation of ERK1/2 and P38 with obvious concentration dependence. Thus, these compounds can inhibit the proliferation of A549 cells through the interruption of ERK1/2 and P38signaling pathways.

Synthesis and anticancer activities of 5,6,7-trimethoxy-N-phenyl(ethyl)-4- aminoquinazoline derivatives

A series of 5,6,7-trimethoxy-N-phenyl(ethyl)-4-aminoquinazoline compounds was prepared by microwave irradiation and conventional heating methods. Compounds 6p, 6q , and 6x strongly inhibited extracellular regulated kinas-1/2 (ERK1/2) phosphorylation induced by epidermal growth factor (EGF) at 1.28 μM in PC3 cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that all compounds had certain anticancer activities, and the IC50 values of 6x were 6.2 ± 0.9, 3.2 ± 0.1, and 3.1 ± 0.1 μM against PC3, BGC823, and Bcap37 cells, respectively. Acridine orange/ethidium bromide staining, Hoechst 33258 staining, DNA ladder, and flow cytometry analyses revealed that 6x induced cell apoptosis in PC3 cells, with apoptosis ratios of 11.6% at 1 μM and 31.8% at 10 μM after 72 h.

QUINAZOLINE COMPOUNDS

Disclosed are compounds having the formula: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, and methods of making and using the same.

2-(Piperazinyl)-4-pyrimioinamines

Herein is disclosed 2-(1-piperazinyl)-4-pyrimidinamine derivatives, acid addition salts thereof, processes for their preparation, methods of using the derivatives and pharmaceutical compositions of the derivatives. The derivatives are distinguished most readily by having novel substituents at position 4 of the piperazinyl radical, the substituents being selected from the group consisting of optionally substituted 2-cycloheptimidazolyl, 1,4,5,6,7,8-hexahydrocycloheptimidazol-2-yl, 2-benzoxazolyl, benzthiazol-2-yl, 1H-2-benzimidazolyl and 1-oxo-2,4,6-cycloheptarien-2-yl. The derivatives are useful for treating hypertension in a mammal.

2-(Piperazinyl)-4-pyrimidinamines

Herein is disclosed 2-(1-piperazinyl)-4-pyrimidinamine derivatives, acid addition salts thereof, processes for their preparation, methods of using the derivatives and pharmaceutical compositions of the derivatives. The derivatives are distinguished most readily by having novel substituents at position 4 of the piperazinyl radical, the substituents being selected from the group consisting of 2-thiazoylyl, oxazolo(4,5-b)pyridin-2-yl and optionally substituted 1-(lower alkyl)-1H-benzimidazol-2-yl. The derivatives are useful for treating hypertension in a mammal.